Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Limitations of Current Dry Eye Therapies | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Treatment Selection in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Brain Stimulation Boosts Vision Recovery After Stroke
A new study from researchers at EPFL introduces a promising non-invasive brain stimulation technique aimed at restoring visual function in stroke patients with hemianopia. The treatment combines visual training with targeted neuromodulation, offering a novel approach to visual rehabilitation in…
Trifocal IOL for Presbyopia Correction
Presbyopia continues to be one of the most significant visual limitations following cataract surgery, even with the use of advanced monofocal or extended-depth intraocular lenses (IOLs). Despite technological progress, achieving consistent vision across near, intermediate and far distance foci remains…
Foundation Fighting Blindness releases 4-year RUSH2A data to public | Ophthalmology Times
(Image Credit: AdobeStock/Ar_TH) Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A, an ongoing natural history study for patients with mutations in the USH2A gene, which causes Usher syndrome type 2A or nonsyndromic retinitis pigmentosa…
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 | Ophthalmology Times
(Image Credit: AdobeStock/Treecha) Opus Genetics has dosed the first patient in its OPGx-BEST1 phase 1/2 clinical trial, BIRD-1, for Best disease (BEST1). Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by…
Enova Advanced EDoF IOL with Light Tailoring Tech
The Enova Advanced® Extended Depth of Focus (EDoF) IOL, developed by VSY Biotechnology GmbH, represents a significant evolution in intraocular lens technology. Built on advanced optical innovation and material science, this lens is designed to offer natural vision, seamless focus, and…
AAO 2025: The rise of presbyopia research | Ophthalmology Times
AnnMarie Hipsley, PDT, PhD, founder of ACE Vision Group spoke to the group’s advances in ocular biomechanics and vision science. The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, towards a systems-level…
AAO 2025: Innovations in surgical visualization and imaging | Ophthalmology Times
Katherine Talcott, MD, a retina specialist at the Cleveland Clinic’s Cole Eye Institute, explores the evolving landscape of retinal surgery, focusing on emerging imaging technologies. She begins by distinguishing 2 main categories of technological advancements: intraoperative optical coherence tomography (OCT)…
Apellis announces 5-year GALE study data in GA | Ophthalmology Times
Image credit: ©Proxima Studio/AdobeStock) Apellis Pharmaceuticals recently announced post hoc analysis data from the GALE extension study. The new data are the result of 5 years of continuous treatment with pegcetacoplan injection (Syfovre) in patients with geographic atrophy (GA) secondary…